Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Work In Process (2016 - 2018)

Amicus Therapeutics filings provide 3 years of Work In Process readings, the most recent being $7.2 million for Q1 2018.

  • On a quarterly basis, Work In Process rose 107.46% to $7.2 million in Q1 2018 year-over-year; TTM through Mar 2018 was $7.2 million, a 107.46% increase, with the full-year FY2017 number at $3.8 million, up 16.17% from a year prior.
  • Work In Process hit $7.2 million in Q1 2018 for Amicus Therapeutics, up from $3.8 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $7.2 million in Q1 2018 to a low of $137000.0 in Q2 2016.
  • Median Work In Process over the past 3 years was $3.6 million (2017), compared with a mean of $4.0 million.
  • The widest YoY moves for Work In Process: up 2643.07% in 2017, down 16.17% in 2017.
  • Amicus Therapeutics' Work In Process stood at $3.3 million in 2016, then grew by 16.17% to $3.8 million in 2017, then skyrocketed by 87.48% to $7.2 million in 2018.
  • The last three reported values for Work In Process were $7.2 million (Q1 2018), $3.8 million (Q4 2017), and $6.9 million (Q3 2017) per Business Quant data.